BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19730362)

  • 21. [Pathological and immunohistochemical analyses of 32 cases of nephrogenic adenoma].
    Shen Q; Sun LH; Wang JH; Liu LB; He Q; Jin J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 45(4):522-6. PubMed ID: 23939154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer].
    Yu T; Zhu SX; Zheng S; Chen SP
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
    Mayes DC; Patterson JW; Ramnani DM; Mills SE
    Am J Clin Pathol; 2007 Apr; 127(4):567-71. PubMed ID: 17369131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
    Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
    Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
    Xiao GQ; Burstein DE; Miller LK; Unger PD
    Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.
    Ng VW; Koh M; Tan SY; Tan PH
    Am J Clin Pathol; 2007 Feb; 127(2):248-53. PubMed ID: 17210521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
    Murphy AJ; Hughes CA; Lannigan G; Sheils O; O'Leary J; Loftus B
    Histopathology; 2007 Jan; 50(2):243-51. PubMed ID: 17222253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
    Cho EY; Kim KM; Park CK; Kim JJ; Sohn TS; Kim DW
    APMIS; 2007 Jun; 115(6):713-8. PubMed ID: 17550379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
    Santinelli A; Mazzucchelli R; Barbisan F; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Am J Clin Pathol; 2007 Oct; 128(4):657-66. PubMed ID: 17875519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
    Varma M; Jasani B
    Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation].
    Pozharisskiĭ KM; Leenman EE; Arzumanov AA
    Arkh Patol; 2005; 67(5):15-9. PubMed ID: 16323473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic adenoma identified on urine cytology using PAX-2 immunostaining.
    Herlitz LC; Tong GX; Hamele-Bena D; Greenebaum E
    Diagn Cytopathol; 2008 Jan; 36(1):47-9. PubMed ID: 18064687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker.
    Tischler V; Fritzsche FR; Gerhardt J; Jäger C; Stephan C; Jung K; Dietel M; Moch H; Kristiansen G
    Histopathology; 2010 May; 56(6):811-5. PubMed ID: 20546348
    [No Abstract]   [Full Text] [Related]  

  • 34. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
    Suzue K; Montag AG; Tretiakova M; Yang XJ; Sahoo S
    Am J Clin Pathol; 2005 Apr; 123(4):553-61. PubMed ID: 15743746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
    Trpkov K; Bartczak-McKay J; Yilmaz A
    Am J Clin Pathol; 2009 Aug; 132(2):211-20; quiz 307. PubMed ID: 19605815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
    Wu X; Zayzafoon M; Zhang X; Hameed O
    Am J Clin Pathol; 2011 Aug; 136(2):239-46. PubMed ID: 21757596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
    Lee WA
    Oncology; 2006; 71(3-4):246-50. PubMed ID: 17652945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of new prostate cancer markers: alpha methylacyl CoA racemase (P504S) and p63].
    Molinié V; Hervé JM; Lugagne PM; Yonneau L; Ellard S; Lebret T; Botto H
    Prog Urol; 2005 Sep; 15(4):611-5. PubMed ID: 16459672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAX2: a reliable marker for nephrogenic adenoma.
    Tong GX; Melamed J; Mansukhani M; Memeo L; Hernandez O; Deng FM; Chiriboga L; Waisman J
    Mod Pathol; 2006 Mar; 19(3):356-63. PubMed ID: 16400326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases].
    Qu F; Xing YF; Xiao YJ; Xiao CG; Guo HQ
    Zhonghua Nan Ke Xue; 2008 Dec; 14(12):1059-62. PubMed ID: 19157222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.